Many women I see grew up hearing the same warning from their mothers: hormones cause cancer. In a lot of families, that one sentence ended the conversation for twenty years.
Perhaps you have been suffering through hot flashes, sleepless nights, and a body that no longer feels like yours because hormone therapy seemed too dangerous to even ask about.
That fear came from somewhere real. It also turned out to be badly overstated for most women, and in late 2025 the FDA began removing the warnings that fed it. It is one of the most common worries I hear from women in New Port Richey. In this article I will walk you through what happened, what the evidence shows today, and how to decide if hormone therapy fits you.
Is Bioidentical Hormone Therapy Safe?
The short answer
For most healthy women who start within ten years of menopause or before age 60, hormone therapy is considered safe and effective for menopause symptoms. Risk depends on your age, health history, the type of hormone, and how it is taken, so the decision should be individual and monitored over time.
Bioidentical hormones have the same molecular structure as the hormones your body makes. Many FDA-approved products are bioidentical, including estradiol patches and gels and micronized progesterone. Compounded versions are also bioidentical, and they come with their own tradeoffs, which I cover below.
What Happened In 2002
In the 1990s, hormone therapy was one of the most prescribed treatments in the country. Then, in July 2002, part of a large federal study called the Women’s Health Initiative was stopped early. Headlines announced that hormones raised the risk of breast cancer, heart attacks, and strokes. Almost overnight, millions of women stopped taking them, and a generation of doctors stopped prescribing them.
The details told a more nuanced story. The women in that study averaged 63 years old, many of them more than a decade past menopause. They took one specific combination: an estrogen made from pregnant horses’ urine and a synthetic progestin. The increase in breast cancer risk in that arm was small in absolute terms, and the arm of the study that used estrogen alone did not show the same increase.
Over the next twenty years, researchers kept reanalyzing the data. A clearer pattern emerged, and timing turned out to be one of the biggest factors. Women who start hormone therapy closer to menopause have a very different risk picture from women who start many years later.
Out of roughly 41 million US women aged 45 to 64, only about 2 million were using hormone therapy as of 2020, according to the FDA. Use collapsed after 2002 and never recovered, even as the evidence shifted.
What Changed
Two decades of follow-up research finally reached the label on the box.
The study stops early
Part of the Women’s Health Initiative halts, and hormone therapy use drops sharply across the country.
The black box arrives
The FDA adds its most serious boxed warning to menopause hormone products, citing heart disease, breast cancer, and dementia.
The FDA reverses course
After an expert panel and a review of the literature, the FDA announces it will remove the boxed warnings for heart disease, breast cancer, and probable dementia.
New labels approved
The first updated labels are approved, with guidance noting benefits for women who start within ten years of menopause, particularly before age 60.
The update did not make hormone therapy risk-free, and it did not remove every warning. The boxed warning about uterine cancer stays in place for women with a uterus who take estrogen without progesterone, because that risk is real. It is also why progesterone is part of the plan for women who still have a uterus.
Major medical groups, including The Menopause Society and the American College of Obstetricians and Gynecologists, supported removing the broad warnings. Some experts still urge caution about overstating the benefits, especially for women with a history of breast cancer. Both of those positions can be true at once, and a good provider will talk with you about both. Testosterone is a separate question with its own evidence, which I cover in my article on low libido after 40.
Bioidentical, Compounded, And FDA-Approved
This is where a lot of confusion lives, so let me be direct about it.
Bioidentical and regulated
Estradiol patches, gels, and sprays, along with micronized progesterone capsules, are bioidentical and FDA-approved. They are tested for consistent dosing, and The Menopause Society recommends them as the first choice for most women.
Custom-made by a pharmacy
Compounded hormones are mixed to order. They can help when a woman needs a dose or form that is not commercially available or has an allergy to an ingredient. They are not FDA-approved, so dosing consistency and safety testing are not held to the same standard.
Hormone pellets are a type of compounded therapy, and they deserve their own honest discussion, which I cover in my article on the pros and cons of hormone pellets. Put simply, bioidentical describes the molecule. It does not by itself make a product safer, and the form, dose, and monitoring matter at least as much.
How hormones enter your body also changes the risk. Estrogen taken as a pill passes through the liver first, which appears to raise the risk of blood clots. Estrogen absorbed through the skin, as a patch or gel, is associated with a lower clot risk in observational research. That is one reason many providers prefer transdermal estrogen.
Who Should Be Cautious
Hormone therapy may not be right for you if you have
- A personal history of breast cancer or uterine cancer
- A history of blood clots, stroke, or heart attack
- Active liver disease
- Unexplained vaginal bleeding that has not been evaluated
Some women in these groups still have safe options, such as low-dose vaginal estrogen for vaginal dryness and other local symptoms. That decision belongs in a careful conversation with your provider.
How I Approach Hormone Therapy In My Practice
My goal is to help you make an informed choice, with the full picture in front of you. When a woman comes to see me about hormones, we start with her symptoms, her cycle or menopause timeline, and her personal and family history. If you are still in the early part of the transition, my article on the early signs of perimenopause is a good place to start.
From there we look at labs and talk through the options side by side, including FDA-approved bioidentical estradiol and progesterone, compounded options when there is a specific reason for them, and non-hormonal approaches. If we start hormone therapy, we use the lowest dose that relieves your symptoms, follow up with labs, and adjust over time. You can read more on our hormone balance and BHRT page and our women’s health page.
Questions To Bring To Your Appointment
Whoever you see, these questions will help you get a clear, personal answer.
- Where am I in the transition?
Ask how your age, cycle history, and symptoms place you, since timing shapes both the benefits and the risks.
- Which form fits my health history?
Ask about patches or gels compared with pills, and what that means for blood clot risk in your situation.
- Do I need progesterone?
If you still have a uterus and take estrogen, the answer should almost always be yes. Ask which type and why.
- Is this FDA-approved or compounded?
Either can be appropriate. Knowing which one you are getting, and the reason, is part of informed consent.
- How will we monitor it?
Ask what labs and check-ins to expect, and how often you and your provider will review the plan.
Frequently Asked Questions
Is bioidentical hormone therapy safer than synthetic hormones?
Bioidentical hormones match the structure of your own hormones, and some research suggests micronized progesterone may carry a lower breast cancer risk than older synthetic progestins. Safety still depends on the dose, the form, your age and health history, and monitoring. The word bioidentical alone does not guarantee a safer product.
Does hormone therapy cause breast cancer?
Combined estrogen and progestin therapy is associated with a small increase in breast cancer risk with longer use. Estrogen alone, used by women without a uterus, has not shown the same increase in major trials. Your personal and family history should guide the decision, and regular screening continues during therapy.
Why did the FDA remove the black box warning on hormone therapy?
After reviewing two decades of research, the FDA concluded the broad warnings about heart disease, breast cancer, and dementia overstated the risks for most women, especially those starting near menopause. It announced the change in November 2025 and approved the first updated labels in February 2026.
Is it too late to start hormone therapy after 60?
Not always, but the risk picture changes. The strongest evidence for benefit is in women who start within ten years of menopause or before age 60. Women who start later need a more careful look at heart and clot risk, and local vaginal estrogen may still be a good option.
How long can you stay on hormone therapy?
There is no universal cutoff. Current guidance supports continuing as long as the benefits outweigh the risks for you, with a review at least once a year. Some women taper off after a few years, and others continue longer with their provider’s monitoring.
You Deserve The Real Picture
For twenty years, fear shaped how women thought about hormone therapy. The evidence now tells a more balanced story, and every woman deserves a provider who will walk through it with her honestly.
Talk through your options with a specialist
Book a free 15-minute discovery call to talk about your symptoms, your history, and if hormone therapy fits you. We see women in our New Port Richey office and by telemedicine throughout Florida, Nevada, and Arizona.
Book Your Free ConsultPrefer to talk today? Call (727) 312-4042